Chinese pharma company BeiGene has agreed to pay Ambrx $10 million upfront to experiment with technology the biotech has developed in a bid accelerate BeiGene’s search for new protein drugs for cancer treatment.
Ambrx says its technology is able to incorporate “non-natural” amino acids into cells like E. coli and CHO, two cell lines commonly used for protein production. BeiGene (NASDAQ: BGNE) sees that method of modifying proteins as a way to bolster its drug development efforts, the company said in a statement Wednesday.
La Jolla, CA-based Ambrx was founded in 2003, one of the slew of biotechs launched by… Read more »
UNDERWRITERS AND PARTNERS
